It seems now is a pretty good time to review ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) . As it appears the company may be on the brink of some nontrivial accomplishments.
ACADIA Pharmaceuticals Inc., primary development efforts involve the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
With the latest financial year loss and a trailing-twelve-month loss, the US$8.7b market-cap company amplified its loss by moving further away from its breakeven target.
Many investors are wondering about the rate at which ACADIA Pharmaceuticals will turn a profit. Below is the link to a high-level summary of the industry analysts’ expectations for the company.
The latest ACADIA Pharmaceuticals analysis
